In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Penumbra Inc.

www.penumbrainc.com

Latest From Penumbra Inc.

Stryker Pushes For Changes To Stroke Care After DAWN

Stryker's Trevo Retriever is the first stent retriever approved by US FDA as a front-line treatment for patients experiencing acute ischemic stroke up to 24 hours from symptom onset, matching the time window recommended in the latest professional treatment guidelines. Now, the company is trying to help the stroke-care system in the US catch up to the science.

Approvals Clinical Trials

Device Debut: Medtronic Pulls Riptide Into Growing Stroke Offering

Riptide complements Medtronic's Solitaire stent retriever revascularization device for the treatment of acute ischemic stroke. The company began rolling out Riptide at this year's International Stroke Conference, which also featured the presentation of important clinical data supporting aspiration as a first-line therapy for stroke.

Neurology Innovation

ISC 2018: COMPASS Supports First-Line Aspiration With Penumbra's System

Results of the COMPASS trial showed that Penumbra's aspiration system is non-inferior to stent-retrievers as a first-line therapy to treat acute ischemic stroke. COMPASS was one of several important device trials featured at the presented at the International Stroke Conference held in Los Angeles.

Neurology Clinical Trials

ISC 2018: DEFUSE 3 Results Bring DAWN Of New Stroke Guidelines

Results of the DEFUSE 3 trial presented at the International Stroke Conference in Los Angeles, along with the previously announced DAWN trial results, support a new recommendation in the American Heart Association/American Stroke Association guidelines on early management of acute ischemic stroke, extending the viable treatment window from six hours to 24 hours in some patients. The change could drive thrombectomy uptake and an aspiration-first approach.

Neurology Diagnostic Imaging
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Penumbra Inc.
  • Senior Management
  • Adam Elsesser, Chmn. & CEO
    Sri Kosaraju, CFO & Head, Strategy
    Lyn Rothman, EVP & CBO
  • Contact Info
  • Penumbra Inc.
    Phone: (510) 748-3200
    1351 Harbor Bay Pkwy.
    Alameda, CA 94502
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register